ASCO 2023 | Identifying patients with HNSCC that will respond to neoadjuvant immunotherapy

Charlotte Zuur, Leiden University Medical Center, Leiden, The Netherlands, discusses the results of a study that looked at T-cell state prior to and in response to neoadjuvant PD-1 and CTLA-4 blockade in patients with head and neck squamous cell carcinoma (HNSCC). The data indicates that the presence of an activated Treg compartment at baseline may be associated with response to this treatment. This interview took place during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.